Phase II/III Randomized Placebo-Controlled Trial of Arimoclomol in SOD1 Positive Familial ALS Amyotrophic Lateral Sclerosis (ALS).
Phase of Trial: Phase II/III
Latest Information Update: 20 Aug 2017
At a glance
- Drugs Arimoclomol (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; Therapeutic Use
- 10 Aug 2017 Status changed from active, no longer recruiting to completed.
- 04 Nov 2013 Planned end date changed from 1 Dec 2013 to 1 Dec 2016 as reported by ClinicalTrials.gov.
- 07 Jan 2013 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.